Identification and Treatment of Group A Beta-Hemolytic Streptococcal Infections: Role of the Pediatrician and the Nurse-Practitioner

1971 ◽  
Vol 18 (1) ◽  
pp. 145-158 ◽  
Author(s):  
Thomas C. Peebles
Keyword(s):  
Nurse Practitioner ◽  
Streptococcal Infections ◽  
Group A

Risk Factors in the Pathogenesis of Invasive Group A Streptococcal Infections: Role of Protective Humoral Immunity

1999 ◽  
Vol 67 (4) ◽  
pp. 1871-1877 ◽  
Author(s):  
Hesham Basma ◽  
Anna Norrby-Teglund ◽  
Yajaira Guedez ◽  
Allison McGeer ◽  
Donald E. Low ◽  
...  
Keyword(s):  
Risk Factors ◽  
Humoral Immunity ◽  
Streptococcal Infections ◽  
Invasive Group ◽  
Group A

Rheumatic Fever Prevention in Industrializing Countries: Problems and Approaches

PEDIATRICS ◽  
1996 ◽  
Vol 97 (6) ◽  
pp. 996-998
Author(s):  
Rachel Snitcowsky
Keyword(s):  
Rheumatic Fever ◽  
Cost Effective ◽  
The United States ◽  
World Health ◽  
Streptococcal Infections ◽  
Industrialized Countries ◽  
The World ◽  
Group A ◽  
Health Organization

Editor's Note The problems resulting from Group A streptococcal infections remain largely unsolved in many of the industrialized countries of the world at the close of the 20th century. The fact that Group A streptococcal infections had assumed almost the role of a nuisance in the United States and Europe, before the beginning of the mid-1980s and 1990s resurgence, stands in marked contrast to the spectrum of streptococcal-related diseases in other parts of the world. Confirmatory epidemiologic data are often difficult to locate, but there is little doubt about the existence and the general magnitude of the problem. Because of this, the World Health Organization (WHO) has targeted Group A streptococcal infections and their sequelae for additional attention. During the last decade the WHO has invested considerable effort toward their control. The need for cost-effective primary and secondary rheumatic fever public health prevention programs is greater in those countries where the magnitude of the problem may be inversely proportional to available resources. Approaches considered routine in North America, in Europe, and in some countries of Latin America and Asia often are nonexistent in industrializing countries where as little as less than $5 per person per year may be reserved for total health care. With these issues in mind, the following perspective was invited to bring these unique problems related to Group A streptococcal infections and their sequelae into focus and to offer suggestions for realistic approaches under less than ideal conditions. We are grateful to Dr Snitcowsky for her comments.

scholarly journals A Cluster of Group A Streptococcal Infections in a Skilled Nursing Facility-the Potential Role of Healthcare Worker Presenteeism

2016 ◽  
Vol 64 (12) ◽  
pp. e279-e284 ◽  
Author(s):  
Miwako Kobayashi ◽  
Meghan M. Lyman ◽  
Louise K. Francois Watkins ◽  
Karrie-Ann Toews ◽  
Leon Bullard ◽  
...  
Keyword(s):  
Healthcare Worker ◽  
Potential Role ◽  
Skilled Nursing Facility ◽  
Streptococcal Infections ◽  
Nursing Facility ◽  
Skilled Nursing ◽  
Group A

Etiology, clinical presentation, laboratory diagnostics, pathogenesis of impetigo and treatment methods

2020 ◽  
pp. 64-70
Author(s):  
Anastasiya Laknitskaya
Keyword(s):  
Streptococcus Pyogenes ◽  
Skin Diseases ◽  
Group A Streptococcus ◽  
Antibiotic Sensitivity ◽  
Antioxidant Defense System ◽  
Laboratory Diagnostics ◽  
Treatment Methods ◽  
Group A ◽  
The Individual

Currently, one of the priority medical and social problems is the optimization of treatment methods for pyoderma associated with Streptococcus pyogenes — group A streptococcus (GAS). To date, the proportion of pyoderma, the etiological factor of which is Streptococcus pyogenes, is about 6 % of all skin diseases and is in the range from 17.9 to 43.9 % of all dermatoses. Role of the bacterial factor in the development of streptococcal pyoderma is obvious. Traditional treatment complex includes antibacterial drugs selected individually, taking into account the antibiotic sensitivity of pathognomonic bacteria, and it is not always effective. Currently implemented immunocorrection methods often do not take into account specific immunological features of the disease, the individual, and the fact that the skin performs the function of not only a mechanical barrier, but it is also an immunocompetent organ. Such an approach makes it necessary to conduct additional studies clarifying the role of factors of innate and adaptive immunity, intercellular mediators and antioxidant defense system, that allow to optimize the treatment of this pathology.

Sign in / Sign up

Export Citation Format

Share Document